Investor relations
Dicot develops a new potency drug that aims to become the first choice globally for the treatment of erectile dysfunction and premature ejaculation.
Dicot intends to initiate the phase 1 study of LIB-01 in August 2023. During the second quarter of 2023, the preclinical studies required to apply for a clinical phase 1 study are under completion. Thereafter, the intention is to enter into strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies in order to be able to introduce LIB-01 to the world market.
Dicot's shares are listed on Spotlight Stock Market and the company has approximately 4,100 shareholders.
IR contact
